Aravive, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-28: Form 8-K; Period of report 2016-12-21; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2016-11-29: Form 8-K; Period of report 2016-11-29; Description 7.01 Regulation FD Disclosure.
- 2016-11-03: Form 8-K; Period of report 2016-11-03; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-10-14: Form 8-K; Period of report 2016-10-11; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-12-28 | 8-K | 2016-12-21 | 1.01 Entry into a Material Definitive Agreement | 1.01 On December 21, 2016, Versartis, Inc. (“we” or “us”) through our subsidiary, Versartis GmbH, entered into a Commercial Supply Agreement with Boehringer Ingelheim Biopharmaceuticals GmbH (“BI”), pursuant to which we engaged BI as a contract manufacturer to manufacture the bulk drug substance for our proprietary long-acting human growth hormone, somavaratan (VRS-317), fill it into the final container and closure and supply such drug product to us for commercial use. | d305777d8k.htm |
| 2016-11-29 | 8-K | 2016-11-29 | 7.01 Regulation FD Disclosure | vsar-8k_20161129.htm | |
| 2016-11-03 | 8-K | 2016-11-03 | 2.02 Results of Operations and Financial Condition | 2.02 On November 3, 2016, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three- and nine-month periods ended September 30, 2016. | vsar-8k_20161103.htm |
| 2016-10-14 | 8-K | 2016-10-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 11, 2016, the Compensation Committee of the Board of Directors of Versartis, Inc. (the “Company”) approved (a) one-time cash bonus payments and (b) grants of restricted stock units (the “RSUs”) for certain of the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission), as set forth in the table below. | d273654d8k.htm |
| 2016-09-29 | 8-K | 2016-09-28 | 8.01 Other Events | 8.01 On September 28, 2016, Versartis, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC, Barclays Capital Inc. and Piper Jaffray & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 4,898,000 shares of our Common Stock. | d257350d8k.htm |
| 2016-09-26 | 8-K | 2016-09-26 | 8.01 Other Events | 8.01 On September 26, 2016, Versartis, Inc. (the “Company”) issued a press release titled “Versartis Initiates Phase 3 Trial of Somavaratan in Japan for Children with Growth Hormone Deficiency Following Completion of Phase 2.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. | d246523d8k.htm |
| 2016-09-15 | 8-K | 2016-09-15 | 7.01 Regulation FD Disclosure | vsar-8k_20160915.htm | |
| 2016-09-12 | 8-K | 2016-09-12 | 8.01 Other Events | vsar-8k_20160912.htm | |
| 2016-09-02 | 8-K | 2016-09-02 | 7.01 Regulation FD Disclosure; 8.01 Other Events | vsar-8k_20160902.htm | |
| 2016-08-09 | 8-K | 2016-08-05 | 1.01 Entry into a Material Definitive Agreement | 1.01 On August 5, 2016, Versartis, Inc. (“we,” “us,” or “the Company”) along with our subsidiary, Versartis GmbH, entered into an Exclusive License and Supply Agreement (the “Agreement”) with Teijin Limited, or Teijin, a pharmaceutical company based in Japan, pursuant to which we granted to Teijin an exclusive license to develop, use, sell, offer for sale, import, and otherwise commercialize, in Japan, any pharmaceutical product incorporating somavaratan (VRS-317). | d208390d8k.htm |
| 2016-07-28 | 8-K | 2016-07-28 | 2.02 Results of Operations and Financial Condition | 2.02 On July 28, 2016, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three- and six-month periods ended June 30, 2016. | d195314d8k.htm |
| 2016-06-03 | 8-K | 2016-05-27 | 1.01 Entry into a Material Definitive Agreement | 1.01 On May 27, 2016, we, through our subsidiary, Versartis GmbH, entered into a Manufacture and Supply Agreement with Owen Mumford Limited, a leading medical device manufacturer, pursuant to which we engaged Owen Mumford to: (1) manufacture a proprietary disposable auto-injector device and (2) assemble and supply a final combination product including the device and somavaratan (VRS-317), our proprietary long-acting form of human growth hormone. | vsar-8k_20160527.htm |
| 2016-05-23 | 8-K | 2016-05-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 18, 2016, Versartis, Inc. (the “Company”) held its Annual Meeting of Stockholders at 2:00 p.m. local time at the Company’s offices located at 4040 Campbell Avenue, Suite 210, Menlo Park, California 94025 (the “Annual Meeting”). | d198413d8k.htm |
| 2016-04-29 | 8-K | 2016-04-28 | 2.02 Results of Operations and Financial Condition | vsar-8k_20160428.htm | |
| 2016-04-04 | 8-K | 2016-04-04 | 8.01 Other Events | vsar-8k_20160404.htm | |
| 2016-04-01 | 8-K | 2016-04-01 | 7.01 Regulation FD Disclosure; 8.01 Other Events | vsar-8k_20160401.htm | |
| 2016-02-18 | 8-K | 2016-02-18 | 2.02 Results of Operations and Financial Condition | 2.02 On February 18, 2016, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three- and twelve-month periods ended December 31, 2015. | vsar-8k_20160217.htm |
| 2016-02-03 | 8-K | 2016-01-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 28, 2016, the Compensation Committee of the Board of Directors of Versartis, Inc. (the “Company”) approved: (a) increases in annual base salaries for 2016, (b) merit bonus awards related to 2015 performance, (c) grants of stock options (the “Options”) and (d) grants of restricted stock units (the “RSUs”) for each of the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission), as set forth in the table below. | vsar-8k_20160128.htm |
| 2016-02-02 | 8-K | 2016-02-02 | 8.01 Other Events | vsar-8k_20160202.htm |